IL6R and neoplasm: Compared with M1-control-shRNA, knockdown of IL6R significantly suppressed intracranial tumour growth and resulted in an increase in survival (median survival: 39 ± 1.6 days vs. 119 ± 4.4 and 108 ± 2.2 days, respectively; Fig. 5a–b).